ARYA Sciences Acquisition Corp IV
ARYD · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.00 | -0.03 | 0.20 | -1.28 |
| FCF Yield | -0.59% | -0.05% | -0.04% | -0.57% |
| EV / EBITDA | -147.83 | 2,351.17 | -85.48 | -1,006.82 |
| Quality | ||||
| ROIC | -2.17% | -9.01% | -2.98% | -0.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.08 | 0.02 | 0.06 | -1.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1,073.16% | -49.24% | 93.39% | -109.45% |
| Safety | ||||
| Net Debt / EBITDA | -5.00 | 57.21 | -1.76 | -15.75 |
| Interest Coverage | 0.00 | -2.43 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |